Success Story: NIW Approved Without RFE! Medicinal Chemistry Scientist from New Zealand Achieves Seamless Success With Our Expert Guidance
Client’s Testimonial:
“Thank you so much!!!!!! I am so grateful for all your hard work!”
On March 5th, 2025, we received another EB-2 NIW (National Interest Waiver) approval for a Scientist II, Medicinal Chemistry in the Field of Medicinal Chemistry (Approval Notice).
General Field: Medicinal Chemistry
Position at the Time of Case Filing: Scientist II, Medicinal Chemistry
Country of Origin: New Zealand
State of Residence at the Time of Filing: California
Approval Notice Date: March 5th, 2025
Processing Time: 15 months, 17 days
Case Summary:
We are pleased to announce the approval of a National Interest Waiver (NIW) petition for a PhD holder whose groundbreaking research focuses on small molecule synthesis and organocatalysis for anticancer drug development. The petition was approved after a thorough review of the client’s academic record, research impact, and demonstrated ability to continue contributing to critical national healthcare needs.
Designing Next-Generation Anticancer Therapies
The petitioner’s proposed endeavor centers on the design and optimization of novel small-molecule therapeutics to improve cancer patient outcomes. Leveraging expertise in synthetic organic chemistry and catalysis, the client develops innovative approaches to construct biologically active compounds. Their work targets difficult-to-treat cancers and addresses urgent medical needs with a strong translational focus.
Currently employed as a medicinal chemist in the biotechnology industry, the petitioner conducts preclinical drug discovery research, synthesizing lead compounds and enhancing their pharmacological profiles. Their work directly supports the development of life-saving oncology drugs, aligning with national priorities in public health and pharmaceutical innovation.
A Proven Track Record of Scientific Impact
At the time of filing, the petitioner had authored 9 peer-reviewed publications, including multiple first-author papers in top-tier journals. Their research has been cited 146 times, and at least two publications rank in the top 10% of most cited articles in their field for their respective publication years. These citations reflect broad recognition and reliance on their work within the scientific community.
In addition, the petitioner has participated in the peer review process for leading academic journals, further establishing their role as a trusted expert in medicinal chemistry.
Endorsements from Esteemed Experts
To further support the case, 2 letters of recommendation from prominent researchers were submitted. These letters attested to the novelty and utility of the petitioner’s methodologies and their contribution to ongoing progress in cancer drug discovery.
“Her specific findings with respect to NHC catalysts and green enantioselective transformation methods, as well as her overall research output, demonstrate that she is an accomplished contributor to the field whose continued presence within the U.S.-based community of researchers is eminently desirable.”
A Strategic and Well-Evidenced PetitionOur legal team highlighted how the petitioner’s education, impactful publication record, and ongoing research position them to continue advancing nationally important work. USCIS agreed, and the petition was approved in just under 16 months without receiving any RFEs.
We are proud to support scientists whose work directly advances public health outcomes and strengthens the nation’s biomedical research leadership.